title: Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
abstract: OBJECTIVE
  Intravitreal anti-vascular endothelial growth factor (VEGF) agents are effective in the treatment of central involving diabetic macular oedema (DMO). Vitreoretinal interface abnormalities (VRIA) are common in patients with DMO, and the effect of these on the response to anti-VEGF treatment is unclear. Furthermore the effect of anti-VEGF agents on the VRIA itself is uncertain.
  
  
  METHODS
  Prospective study of consecutive patients treated with ranibizumab (RZB) for DMO as part of routine clinical care in one eye unit over a 1-year period. Visual acuity (Va), central retinal thickness (CRT) and injection frequency data was recorded on an electronic database. Treatment was initiated with four monthly RZB injections and then a monthly PRN regime. All patients underwent high-density spectral-domain optical coherence tomography (SDOCT) at baseline and 12 months. The SDOCTs were graded by two observers masked to the outcome.
  
  
  RESULTS
  One hundred and four eyes (77 patients) were included in the analysis. The mean age was 62 years, and 62% were male. The mean presenting vision was 62 letters and CRT 472 μm. Eighty eyes retained stable Va, and 17 had an improvement in Va. At baseline, 39 eyes had associated focal vitreomacular adhesion (VMA) and by 12 months this reduced to 30 (p = 0.04), with 12 releasing VMA and three developing it. Patients with VMA had significantly better final Va than those without VMA. Improvement in CRT was greatest in those where VMA released during the study. Forty-five eyes had some degree of foveal involving epiretinal membrane (ERM) at baseline, and 28 were considered to have clinically significant ERM. There was no clinically relevant change in ERM during the study. Patients with significant ERM at baseline had a lower final vision. Multivariate analysis showed that ERM and more severe retinopathy at baseline were predictive of less visual improvement (p < 0.01). Shorter intraretinal cyst length, ERM and the absence of VMA at baseline were predictive of a worsened anatomical response (p < 0.001).
  
  
  CONCLUSIONS
  VRIA are related to outcome in patients treated with RZB. ERM was associated with a worsened visual and anatomic response, and VMA with an improved anatomical response particularly when spontaneous VMA release occurred during treatment. The presence and severity of ERM was not affected by RZB treatment.
authors.affiliation: Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK.
authors.forename: Yun
authors.initials: Y
authors.lastname: Wong
authors.affiliation: Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK. David.steel@ncl.ac.uk.|Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK. David.steel@ncl.ac.uk.
authors.forename: David H W
authors.initials: DHW
authors.lastname: Steel
authors.affiliation: Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK.
authors.forename: Maged S
authors.initials: MS
authors.lastname: Habib
authors.affiliation: Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK.
authors.forename: Alex
authors.initials: A
authors.lastname: Stubbing-Moore
authors.affiliation: Sunderland Eye Infirmary, Queen Alexandra Road, Sunderland, SR2 9HP, UK.
authors.forename: Dalvir
authors.initials: D
authors.lastname: Bajwa
authors.affiliation: School of Mathematics & Statistics, Newcastle University, Newcastle Upon Tyne, UK.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Avery
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D003930:Diabetic Retinopathy / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012160:Retina / Q000187:drug effects / Q000473:pathology*; D013997:Time Factors; D000267:Tissue Adhesions / Q000175:diagnosis* / Q000209:etiology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
keywords: Anti VEGF; Diabetic macular oedema; Epiretinal membrane; Ranibizumab; Real-world outcomes; Vitreomacular adhesion; Vitreoretinal interface abnormality